MedTrace Logo

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

NCT06767540 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2025-01-10

No results posted yet for this study

Summary

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.

Conditions

Interventions

DRUG

Placebo

placebo subcutaneous injection Q2W until week 46.

DRUG

placebo

placebo subcutaneous injection Q3W until week 45.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2027-07-10
Completion
2027-07-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06767540 on ClinicalTrials.gov